274 related articles for article (PubMed ID: 31076504)
1. Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic
Thorwarth D; Welz S; Mönnich D; Pfannenberg C; Nikolaou K; Reimold M; La Fougère C; Reischl G; Mauz PS; Paulsen F; Alber M; Belka C; Zips D
J Nucl Med; 2019 Dec; 60(12):1698-1704. PubMed ID: 31076504
[TBL] [Abstract][Full Text] [Related]
2. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
Lee NY; Mechalakos JG; Nehmeh S; Lin Z; Squire OD; Cai S; Chan K; Zanzonico PB; Greco C; Ling CC; Humm JL; Schöder H
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):2-13. PubMed ID: 17869020
[TBL] [Abstract][Full Text] [Related]
3. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
[TBL] [Abstract][Full Text] [Related]
4. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
[TBL] [Abstract][Full Text] [Related]
5. Geometric analysis of loco-regional recurrences in relation to pre-treatment hypoxia in patients with head and neck cancer.
Boeke S; Thorwarth D; Mönnich D; Pfannenberg C; Reischl G; La Fougère C; Nikolaou K; Mauz PS; Paulsen F; Zips D; Welz S
Acta Oncol; 2017 Nov; 56(11):1571-1576. PubMed ID: 28891398
[TBL] [Abstract][Full Text] [Related]
6. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
[TBL] [Abstract][Full Text] [Related]
7. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study.
Chang JH; Wada M; Anderson NJ; Lim Joon D; Lee ST; Gong SJ; Gunawardana DH; Sachinidis J; O'Keefe G; Gan HK; Khoo V; Scott AM
Acta Oncol; 2013 Nov; 52(8):1723-9. PubMed ID: 23317145
[TBL] [Abstract][Full Text] [Related]
9. Assessment of tumor hypoxia in spontaneous canine tumors after treatment with OMX, a novel H-NOX oxygen carrier, with [
Choen S; Kent MS; Loucks FA; Winger JA; Zwingenberger AL
BMC Vet Res; 2024 May; 20(1):196. PubMed ID: 38741109
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.
Eschmann SM; Paulsen F; Reimold M; Dittmann H; Welz S; Reischl G; Machulla HJ; Bares R
J Nucl Med; 2005 Feb; 46(2):253-60. PubMed ID: 15695784
[TBL] [Abstract][Full Text] [Related]
11. Monitoring early response to chemoradiotherapy with
Grkovski M; Lee NY; Schöder H; Carlin SD; Beattie BJ; Riaz N; Leeman JE; O'Donoghue JA; Humm JL
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1682-1691. PubMed ID: 28540417
[TBL] [Abstract][Full Text] [Related]
12. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
Kikuchi M; Yamane T; Shinohara S; Fujiwara K; Hori SY; Tona Y; Yamazaki H; Naito Y; Senda M
Ann Nucl Med; 2011 Nov; 25(9):625-33. PubMed ID: 21720778
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH
Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199
[TBL] [Abstract][Full Text] [Related]
14. Multiparametric Imaging of Tumor Hypoxia and Perfusion with
Grkovski M; Schöder H; Lee NY; Carlin SD; Beattie BJ; Riaz N; Leeman JE; O'Donoghue JA; Humm JL
J Nucl Med; 2017 Jul; 58(7):1072-1080. PubMed ID: 28183993
[TBL] [Abstract][Full Text] [Related]
15. Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
Löck S; Linge A; Seidlitz A; Bandurska-Luque A; Nowak A; Gudziol V; Buchholz F; Aust DE; Baretton GB; Zöphel K; Steinbach J; Kotzerke J; Overgaard J; Zips D; Krause M; Baumann M; Troost EGC
Radiother Oncol; 2019 Jun; 135():43-50. PubMed ID: 31015169
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Optimal Post-Injection Timing of Hypoxic Imaging with
Kawamura M; Yoshimura M; Shimizu Y; Sano K; Ishimori T; Nakamoto Y; Mizowaki T; Hiraoka M
Mol Imaging Biol; 2021 Aug; 23(4):597-603. PubMed ID: 33475945
[TBL] [Abstract][Full Text] [Related]
17. ¹⁸F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with ¹⁸F-FMISO.
Chen L; Zhang Z; Kolb HC; Walsh JC; Zhang J; Guan Y
Nucl Med Commun; 2012 Oct; 33(10):1096-102. PubMed ID: 22836736
[TBL] [Abstract][Full Text] [Related]
18.
Yu W; Qiao F; Su X; Zhang D; Wang H; Jiang J; Xu H
Biomed Pharmacother; 2019 Nov; 119():109454. PubMed ID: 31526971
[TBL] [Abstract][Full Text] [Related]
19. Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy.
Zschaeck S; Löck S; Hofheinz F; Zips D; Saksø Mortensen L; Zöphel K; Troost EGC; Boeke S; Saksø M; Mönnich D; Seidlitz A; Johansen J; Skripcak T; Gregoire V; Overgaard J; Baumann M; Krause M
Radiother Oncol; 2020 Aug; 149():189-196. PubMed ID: 32417350
[TBL] [Abstract][Full Text] [Related]
20. Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy.
Lee N; Nehmeh S; Schöder H; Fury M; Chan K; Ling CC; Humm J
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):101-8. PubMed ID: 19203843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
